Walbrook PR

Financial PR and IR for smallcap and AIM companies

[Walbrook PR @WalbrookPR]

✅@hargreaves_plc (AIM: #HSP) announces that they have been awarded a 15-year contract providing logistics services to the UK Deposit Return Scheme

https://t.co/waxNXpc6r2

Read more below ⤵️

[Hargreaves Services plc @hargreaves_plc]

We are delighted to announce that we have been awarded a 15-year contract for logistics services for the UK Deposit Return Scheme (DRS).

[Walbrook PR @WalbrookPR]

https://t.co/kllR5qXJ9w

[Walbrook PR @WalbrookPR]

⬆️The contract with Re. Group will commence October 2027 and is expected to have a positive impact on FY28 performance, before its full impact in FY29.

[Walbrook PR @WalbrookPR]

🔗 https://t.co/BudyJ9EKZa

[Walbrook PR @WalbrookPR]

✅@Renalytix - US Kidney Care National Plan reinforces kidneyintelX.dkd opportunity

🚀 Marks a shift in US policy from managing kidney failure towards preventing it
➡️ Aligns directly with kidneyintelX.dkd, #RENX's FDA-authorized and Medicare-reimbursed prognostic blood test

[Walbrook PR @WalbrookPR]

🔑 Key themes of the Plan and their relevance:

✅ Prevention is now the stated federal priority
✅ kidneyintelX.dkd’s patient population is identified as the problem to solve
✅ Expanding early detection
✅ Implementing precision-based care

Read here: https://t.co/J8LH1NrOVF

[Walbrook PR @WalbrookPR]

🔗 https://t.co/52zi1SqFSg

[Walbrook PR @WalbrookPR]

➡️@VericiDx (AIM: #VRCI) welcomes the Launch of US Kidney Care National Plan

The 2026 Kidney Care National Plan centres on 3 priorities:

✅ Prevent Kidney Failure
🩸 Improve Dialysis Care and Expand Patient Choice
🚀 Reform Transplantation

Read here: https://t.co/J8LH1NrOVF

[Walbrook PR @WalbrookPR]

https://t.co/3SZm5Qub92

[Walbrook PR @WalbrookPR]

@FsnAntibodies plc (AIM: #FAB) - Contract Win

✅ New project covering the transient gene expression of a client’s lead antibody and a subsequent cryogenic electron microscopy study under an existing master services agreement with a global pharmaceutical company

[Walbrook PR @WalbrookPR]

📈Represents further repeat business from a major pharmaceutical Client and supports Fusion’s current strategy
💲The project is expected to generate revenues in excess of £85,000 for the Company

[Walbrook PR @WalbrookPR]

🔗 https://t.co/9GnkkTLiEz

[Walbrook PR @WalbrookPR]

➡️@VericiDx Kidney Transplant Tx Clinical Study

🥼Order with Asahi Kasei Therapeutics for Phase 2 clinical trial
🩸#VRCI will perform blood-based biomarker testing, including PTRA
✅Use of RNA signature tests reflects growing role of molecular diagnostics in clinical development

[Walbrook PR @WalbrookPR]

🔗 https://t.co/paU0WxSR4z

[Walbrook PR @WalbrookPR]

➡️@Parsortix (AIM: #CLBX) - MSA with a Swiss biotech company

✒️Entered into MSA & a Statement of Work for a Radio-Pharmaceutical Clinical Study
✅In 2025, the market size of radioligand-therapy market had a value of ~ $3.0b, increasing to between $10.9b and $15.9b by 2035

[Walbrook PR @WalbrookPR]

RNS -
https://t.co/Mlx7DSdNrX

Harin Vaghela, Chief Product Officer, provides an overview of the new Invention Evaluator platform -
https://t.co/9dFdFztB3k

[Walbrook PR @WalbrookPR]

⏩@GenIPplc (AIM: #GNIP) - Soft launch of Invention Evaluator platform

✅Soft launch of its Invention Evaluator platform
📈Platform provides a single place for customers to submit inventions, receive results, and compare opportunities.

[Walbrook PR @WalbrookPR]

⬆️Greater automation reduces delivery time and increases capacity,
👏The platform is currently being trialled by several customers across Chile, Singapore, the United States and the United Kingdom ahead of the planned commercial launch in December.

[Walbrook PR @WalbrookPR]

🔗 https://t.co/lN70XqAHkD

[Walbrook PR @WalbrookPR]

➡️@edenresearch - Attendance at Annual Biocontrol Industry Meeting

👥#EDEN commercial team, including Sean Smith, CEO, and Alex Abrey, CFO, will be attending ABIM in Basel, Switzerland from 20 to 22 October 2026
🌍Leading international event for global biocontrol industry